ROGER WILLIAMS MEDICAL CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1878-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.rwmc.org
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Phase 1
Withdrawn
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Roger Williams Medical Center
- Registration Number
- NCT04270929
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
Phase 1
Completed
- Conditions
- Liver Metastases
- Interventions
- Biological: anti-CEA CAR-T cells
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT02850536
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸Roger Williams Medical Center, Providence, Rhode Island, United States
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Phase 1
Completed
- Conditions
- Liver Metastases
- Interventions
- Biological: anti-CEA CAR-T cellsDevice: Sir-Spheres
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT02416466
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Phase 1
Suspended
- Conditions
- Monitor Adverse Events
- Interventions
- Drug: Anti-PSMA Designer T Cells
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01929239
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds
Phase 1
Terminated
- Conditions
- Non Healing Wounds
- Interventions
- Genetic: Stem Cell
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT01751282
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas
Phase 2
Suspended
- Conditions
- Metastatic Cancers
- Interventions
- Genetic: Gene Modified T Cells
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT01723306
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Phase 1
Completed
- Conditions
- Liver Metastases
- Interventions
- Biological: anti-CEA 2nd generation designer T cells
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT01373047
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- NeoplasmsTumorsMetastatic CancerSolid Tumors
- Interventions
- Biological: EGFRBi-armed autologous activated T cells
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT01081808
- Locations
- 🇺🇸
Roger Willaims Medical Center, Providence, Rhode Island, United States
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Phase 1
Terminated
- Conditions
- Colorectal Cancer
- Interventions
- Biological: Gene Modified T Cells
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT00673322
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Phase 1
Suspended
- Conditions
- Breast Cancer
- Interventions
- Biological: Gene Modified T Cells and Interleukin 2Biological: Gene Modified T Cells
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Roger Williams Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT00673829
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
🇺🇸Tufts University Medical Center, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath